Expression Level of TGFbeta1 and VEGF Gene in Acute Myeloid Patients and Its Clinical Prognostic Value

OBJECTIVE: To study the expression level of TGFbeta1 and VEGF gene in patients with acute myeloid leukemia (AML) and its clinical prognostic value. METHODS: Seventy-eight AML patients treated in our hospital from July 2016 to September 2018 were selected. After isolation of bone marrow mononuclear cells from the patients, the levels of TGFbeta1 and VEGF genes were detected by RT-PCR, and the correlation of TGFbeta1 with VEGF genes and clinical characteristics of AML patients was analyzed. OS and EFS of the patients were evaluated by Kaplan-Meier, and Cox risk ratio model was used to analyze the prognostic risk factors of AML patients. RESULTS: The relative expression level of TGFbeta1 gene in AML patients was 0.32+/-0.04, which was significantly lower than that in control group (P<0striped box05). The relative expression level of vascular endothelial growth factor(VEGF) gene in the patients was 2.65+/-0.15, which was significantly higher than that in the control group (P<0.05). The levels of TGFbeta1 and VEGF genes significantly correlated with leukocyte count, hemoglobin, platelet and peripheral blast levels in AML patients (P<0.05). The level of TGFbeta1 in AML patients with complete remission was higher than that in patients with partial remission or non-remission (P<0.05). The level of TGFbeta1 in AML patients with partial remission was significantly higher than that in patients with non-remission (P<0.05). The level of VEGF in AML patients with complete remission was lower than at in patients with partial remission or non-remission (P<0.05). The level of VEGF in AML patients with partial remission was significantly lower than that in patients with non-remission (P<0.05). Kaplan-Meier survival analysis showed that OS and DFS in AML patients with high expression of TGFbeta1 were better than those in patients with low expression of TGFbeta1 (P<0.05), OS and DFS in AML patients with low expression of VEGF were better than those in patients with high expression of VEGF (P<0.05). Multivariate Cox regression analysis showed that platelet, TGFbeta1 and VEGF gene were independent influencing factors of OS (P<0.05). Leukocyte, TGFbeta1 and VEGF gene were independent influencing factors of DFS (P<0.05). CONCLUSION: Decreased expression of TGFbeta1 and increased expression of VEGF gene in AML patients closely relate to the poor prognosis of AML patients, which can provide reference for improving clinical efficacy of AML patients.